Skip to content
FORSIDEN
Log ind Opret konto
  • Kategorier
  • Seneste
  • Etiketter
  • Populære
  • Verden
  • Bruger
  • Grupper
Temaer
  • Light
  • Brite
  • Cerulean
  • Cosmo
  • Flatly
  • Journal
  • Litera
  • Lumen
  • Lux
  • Materia
  • Minty
  • Morph
  • Pulse
  • Sandstone
  • Simplex
  • Sketchy
  • Spacelab
  • United
  • Yeti
  • Zephyr
  • Dark
  • Cyborg
  • Darkly
  • Quartz
  • Slate
  • Solar
  • Superhero
  • Vapor

  • Default (No Skin)
  • No Skin
Kollaps
  1. Debatforum
  2. Kategorier
  3. Genmab
  4. Genmab — Marts 2023

Genmab — Marts 2023

Planlagt Fastgjort Låst Flyttet Genmab
499 Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • P Offline
    P Offline
    Pensionisten
    wrote on sidst redigeret af
    #486

    Den optur, der startede 10. marts synes sat lidt på pause. Håber på lidt positivt nyt, der kan give fornyede kræfter.

    1 Reply Last reply
    0
    • E Offline
      E Offline
      E_L
      wrote on sidst redigeret af
      #487

      interesting, a new Epcoritamab trial +Venetoclax by the Haemato Oncology Foundation in the Netherlands, with Nordic & German CLL Study Groups, don't see genmab or abbvie - Venetoclax Treatment (26 Cycles) With 6 Cycles or 12 Cycles of Epcoritamab in Patients With Relapsed or Refractory CLL or SLL (AETHER) https://clinicaltrials.gov/ct2/show/NCT05791409

      1 Reply Last reply
      0
      • E Offline
        E Offline
        E_L
        wrote on sidst redigeret af
        #488

        Amivantamab efficacy in pretreated NSCLC with EGFR Exon 20 insertion mutations persists long term https://dailyreporter.esmo.org/european-lung-cancer-congress-2023/elcc-2023/amivantamab-efficacy-in-pretreated-nsclc-with-egfr-exon-20-insertion-mutations-persists-long-term

        1 Reply Last reply
        0
        • SolsenS Offline
          SolsenS Offline
          Solsen
          wrote on sidst redigeret af
          #489

          Rigtig spændende med combi med venetoclax, som er et fantastisk stof. Det kan der komme noget stort ud af for Genmab/Abbvie og patienterne.

          1 Reply Last reply
          0
          • StockBullS Offline
            StockBullS Offline
            StockBull
            wrote on sidst redigeret af
            #490

            Det er i vores mørkeste øjeblikke, at vi skal fokusere for at se lyset.

            1 Reply Last reply
            0
            • E Offline
              E Offline
              E_L
              wrote on sidst redigeret af
              #491

              Venetoclax is also from AbbVie if i am not mistaken...

              1 Reply Last reply
              0
              • SolsenS Offline
                SolsenS Offline
                Solsen
                wrote on sidst redigeret af
                #492

                Correct

                1 Reply Last reply
                0
                • S Offline
                  S Offline
                  Sukkeralf
                  wrote on sidst redigeret af
                  #493

                  In partnership with Roche/Genentech though

                  1 Reply Last reply
                  0
                  • E Offline
                    E Offline
                    E_L
                    wrote on sidst redigeret af
                    #494

                    https://twitter.com/tnewsomdavis/status/1641480986746662913 "Very surprised that 1/3 of audience opted
                    for 1L Amivantamab"

                    1 Reply Last reply
                    0
                    • E Offline
                      E Offline
                      E_L
                      wrote on sidst redigeret af
                      #495

                      Daratumumab, an anti-CD38 effective in two cases of severe refractory myositis https://www.institut-myologie.org/en/2023/03/30/daratumumab-an-anti-cd38-effective-in-two-cases-of-severe-refractory-myositis/

                      1 Reply Last reply
                      0
                      • StockBullS Offline
                        StockBullS Offline
                        StockBull
                        wrote on sidst redigeret af
                        #496

                        Morn, Fibonacci købssignal https://www.proinvestor.com/boards/111776/

                        1 Reply Last reply
                        0
                        • E Offline
                          E Offline
                          E_L
                          wrote on sidst redigeret af
                          #497

                          https://onkologisktidsskrift.dk/behandlinger/lungekraeft/2835-nye-data-for-rybrevant-bekraefter-stoffets-potentiale-mod-egfr-exon-20-muteret-nsclc.html Nye data for Rybrevant bekræfter stoffets potentiale mod EGFR exon 20-muteret NSCLC

                          1 Reply Last reply
                          0
                          • E Offline
                            E Offline
                            E_L
                            wrote on sidst redigeret af
                            #498

                            AMGEN on Horizon acquisition: We believe that our decades of leadership in inflammation and nephrology, combined with our global presence and world-class biologic capabilities, will enable us to reach many more patients with life-changing medicines like TAVNEOS and TEPEZZA than either company could achieve on its own. https://www.amgen.com/stories/2023/03/2022-letter-to-shareholders

                            1 Reply Last reply
                            0
                            • troldmandenT Offline
                              troldmandenT Offline
                              troldmanden
                              wrote on sidst redigeret af
                              #499

                              Nå mon vi skal have et positivt udfald af voldgift før 3000 kan brydes og agere ny bund. NPV impact er signifikant større på udfaldet af den afgørelse end af epco. Så bliver rart at komme på den anden side af retssagen. At få reduceret usikkerheden der tynger

                              1 Reply Last reply
                              0
                              • E Offline
                                E Offline
                                E_L
                                wrote on sidst redigeret af
                                #500

                                end of month & quarter. 4th red month in a row.

                                    • 28/2 18:07
                                      af E L
                                      3rd red month in a row. Since the lows of 2011 we only once had 4 negative months in a row, at the end of 2017
                                1 Reply Last reply
                                0

                                Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                With your input, this post could be even better 💗

                                Tilmeld Log ind
                                Svar
                                • Svar som emne
                                Login for at svare
                                • Ældste til nyeste
                                • Nyeste til ældste
                                • Most Votes


                                • Log ind

                                • Har du ikke en konto? Tilmeld

                                • Login or register to search.
                                Powered by NodeBB Contributors
                                • First post
                                  Last post
                                0
                                • Kategorier
                                • Seneste
                                • Etiketter
                                • Populære
                                • Verden
                                • Bruger
                                • Grupper